Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study

Hanaire-Broutin, H; Broussolle, C.; Jeandidier, N.; Renard, Éric; Guerci, Bruno; Haardt, M.J.; Lassmann-Vague, V.

doi:10.2337/diacare.18.3.388

Cited by 83 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Langzeitstudien, bei denen die intra peritoneale Insulintherapie über implan tierbare Insulinpumpen erfolgte, konnten ein erheblicher Rückgang von schweren Hypoglykämien sowie sehr gute HbA1c Ergebnisse mit stark reduzierter Blutglu koselabilität gezeigt werden [2,4,6]. Der Grund für die guten Ergebnisse ist die Art der Insulinsubstitution, mit der physiolo gischen Verteilung der Insulinkonzent rationen zwischen lebernahem und pe ripherem Gewebe.…”

Section: Intraperitoneale Insulininfusionunclassified

Lösungsansätze bei frustraner Insulinpumpentherapie

Liebl

2009

Diabetologe

View full text Add to dashboard Cite

Section: Intraperitoneale Insulininfusionunclassified

Lösungsansätze bei frustraner Insulinpumpentherapie

Liebl

2009

Diabetologe

View full text Add to dashboard Cite

“…Periodic (mostly in 9-month intervals) rinsing by NaOH of the insulin pathway inside the pump can both prevent and fix this aggregation problem (21). In spite of this remaining issue, IP insulin infusion from implantable pumps provides lower average HbA1c levels, a significantly improved blood glucose stability and a dramatic decrease of severe hypoglycemic events when compared to SC insulin infusion (18,22,23). Implantable insulin pumps have been approved for clinical use in European Union since 1995.…”

Section: Feasibility and Performance Of Ip Insulin Deliverymentioning

confidence: 99%

“…These latter events were likely promoted by the pulsatile output of insulin from these pump models. Longterm use of implantable pumps for IP insulin infusion, mainly investigated by the French EVADIAC group, has been shown as safe and reliable (18,19). Improvements of implantation procedures and of catheter components have allowed a dramatic reduction of complications at implantation site as well as of catheter obstructions which were respectively reported in early experiments (20).…”

Section: Feasibility and Performance Of Ip Insulin Deliverymentioning

confidence: 99%

Clinical experience with an implanted closed-loop insulin delivery system

Renard

2008

Arq Bras Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

Aim: to report the first clinical experience with a prototype of implanted artificial beta-cell. Methods: the long-term sensor system ® project assessed the feasibility of glucose control by the combined implantation of a pump for peritoneal insulin delivery and a central intravenous glucose sensor, connected physically by a subcutaneous lead and functionally by Pid algorithms. it was performed in 10 type 1 diabetic patients from 2000 to 2007. Results: no harmful complication related to implants occurred. insulin delivery was affected by iterative but reversible pump slowdowns due to insulin precipitation. glucose measurement by the intravenous sensors correlated well with meter values (r = 0.83-0.93, with a mean absolute deviation of 16.5%) for an average duration of 9 months. uploading of pump electronics by Pid algorithms designed for closed-loop insulin delivery allowed in-patient 48 hourtrials. Conclusion: Although the concept of a fully implantable artificial beta-cell has been shown as feasible, improvements in the sensor structure to increase its longevity and decrease sensor delay that affected closed-loop control at meal-times are expected. Objetivo: relatar a primeira experiência clínica com um protótipo de célula-beta artificial implantável. Métodos: o projeto de um sistema sensor de longo Prazo avaliou a possibilidade do controle glicêmico através do implante combinado de uma bomba de infusão de insulina peritoneal e um gluco -sensor endovenoso central -conectados fisicamente por um dispositivo subcutâneo e funcionalmente por algoritmos Pid (integral and derivative). este projeto envolveu 10 pacientes com diabetes melito tipo 1 de 2000 a 2007. Resultados: complicações significativas relacionadas aos implantes não ocorreram. A liberação de insulina pela bomba sofreu o efeito de perío-dos de lentificação interativo, mas reversível, devido a precipitação do peptídeo. As medidas da glicose pelo sensor endovenoso mostraram boa correlação com os valores do glicosímetro (r = 0,83-0,93, com desvio médio absoluto de 16,5%) durante período médio de 9 meses. os dados para construção dos algoritmos Pid do sistema de alça fechada de liberação de insulina foram obtidos a partir de 12 pacientes que permaneceram internados com esse sistema durante 48 horas com refeições que continham 40 a 70 g de

show abstract

“…7,[16][17][18][19][20][21][22][23][24] Glycemic variability (standard deviation of capillary glucose) was also smaller with CIPII therapy. 17,20,[22][23][24][25] Moreover, long-term data from small, nonblinded studies show stabilization of HbA1c levels and lower risk of hyperglycemia.…”

Section: Technology Reportmentioning

confidence: 99%

A New Optimized Percutaneous Access System for CIPII

Garcia-Verdugo¹,

Erbach²,

Schnell

2017

J Diabetes Sci Technol

View full text Add to dashboard Cite

In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a favored treatment alternative for patients with subcutaneous insulin resistance, mainly due to its ability of mimicking physiological conditions of insulin absorption. CIPII has been shown to improve glycemic control as well as to reduce hypoglycemic events and to lead to increased patient satisfaction and quality of life (QoL). Among CIPII delivery systems, Diaport stands out due to its low side effects, its demonstrated clinical efficacy and the potential for integration into closed-loop systems.

show abstract

Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study

Cited by 83 publications

References 0 publications

Lösungsansätze bei frustraner Insulinpumpentherapie

Lösungsansätze bei frustraner Insulinpumpentherapie

Clinical experience with an implanted closed-loop insulin delivery system

A New Optimized Percutaneous Access System for CIPII

Contact Info

Product

Resources

About